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        The mammalian NOTCH proteins are het-
erodimeric transmembrane receptors that con-
trol cell proliferation, apoptosis, and cell fate 
during the development of diverse cellular lin-
eages (  1  ). Aberrant NOTCH signaling has been 
extensively linked to cancer and development. 
In mouse models, constitutive NOTCH signal-
ing contributes to the genesis of breast cancer, 
medulloblastoma, and T cell leukemia (  2  –  9  ), 
whereas in human cancer its role is best exem-
plifi  ed by T cell acute lymphoblastic leukemias 
(T-ALLs). Human   NOTCH1   was fi  rst discov-
ered as a gene activated at the breakpoint of the 
t(7;9), a very rare chromosomal translocation 
that fuses the intracellular form of NOTCH1 
to the T cell receptor      locus in lymphoblasts 
of T-ALL patients (  10  ). Recently, 50% of hu-
man T-ALL cell lines and primary patient sam-
ples were shown to harbor activating mutations 
in   NOTCH1   that result in aberrant NOTCH 
signaling (  11  ). Although mutations that di-
rectly activate NOTCH receptors have not 
been identifi  ed in other types of human can-
cers, there is abundant evidence to support the 
importance of deregulated NOTCH activity in 
the development of ovarian cancer (  12  ), breast 
cancer (  13  ), anaplastic large cell lymphoma and 
Hodgkin disease (  14  ), melanoma (  15  ), gliomas 
(  16  ), lung carcinomas (  17, 18  ), and cancers 
of the pancreas (  18  ) and prostate (  19  ). Hence, 
modulation of the NOTCH signaling cascade 
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      -secretase inhibitors (GSIs) can block NOTCH receptor signaling in vitro and therefore 
offer an attractive targeted therapy for tumors dependent on deregulated NOTCH activity. 
To clarify the basis for GSI resistance in T cell acute lymphoblastic leukemia (T-ALL), we 
studied T-ALL cell lines with constitutive expression of the NOTCH intracellular domain 
(NICD), but that lacked C-terminal truncating mutations in   NOTCH1  . Each of the seven cell 
lines examined and 7 of 81 (8.6%) primary T-ALL samples harbored either a mutation or 
homozygous deletion of the gene   FBW7  , a ubiquitin ligase implicated in NICD turnover. 
Indeed, we show that FBW7 mutants cannot bind to the NICD and defi  ne the phosphode-
gron region of the NICD required for FBW7 binding. Although the mutant forms of FBW7 
were still able to bind to MYC, they do not target it for degradation, suggesting that 
stabilization of both NICD and its principle downstream target, MYC, may contribute to 
transformation in leukemias with   FBW7   mutations. In addition, we show that all seven 
leukemic cell lines with   FBW7   mutations were resistant to the MRK-003 GSI. Most of 
these resistant lines also failed to down-regulate the mRNA levels of the NOTCH targets 
  MYC   and   DELTEX1   after treatment with MRK-003, implying that residual NOTCH signaling 
in T-ALLs with   FBW7   mutations contributes to GSI resistance. 1814   FBW7   MUTATION IN T-ALL | O  ’  Neil et al.
fi  ve GSI-sensitive cell lines, indicating that MRK-003 acts by 
inducing apoptosis as well as by blocking cell growth (  Fig. 1 B  ). 
Importantly, the altered proliferation, cell cycle arrest, and 
increase in apoptosis could be rescued by overexpressing the 
NICD, demonstrating that these eff  ects indeed result from 
inhibition of the NOTCH signaling pathway (  24   and unpub-
lished data). The cell counts, cell cycle profi  les, and percent-
ages of apoptotic cells in the remaining 15 T-ALL cell lines 
were not aff  ected by treatment with MRK-003 (  Fig. 1, 
C   and D, and   Table I  ). 
  NICD levels are high in several T-ALL cell lines without 
truncating mutations in   NOTCH1   
  Treatment with MRK-003 led to reduced levels of NICD in 
each of the T-ALL cell lines in which the intracellular pro-
tein could be detected, indicating that the compound eff  ec-
tively inhibited NOTCH1 cleavage at the cell surface (  Fig. 1 E  ). 
However, only a subset of the 20 T-ALL cell lines had a GSI-
sensitive cellular phenotype, indicating that a resistant pheno-
type can be observed with or without evidence for constitutive 
NOTCH signaling (i.e., without detectable expression of 
NICD;   Table I   and   Fig. 1 E  ). Western blot analysis also dem-
onstrated that all of the cell lines with C-terminal truncating 
mutations of   NOTCH1   expressed high levels of NICD 
(  Table I   and   Fig. 1 E  ), refl  ecting aberrant activation of the 
NOTCH pathway. Interestingly, there were seven cell lines 
without C-terminal truncating mutations in   NOTCH1   that 
also expressed high levels of NICD (RPMI8402, CEM, 
BE13, DU528, HSB2, Jurkat, and PEER), implying that 
NOTCH is stabilized in these cell lines through a mechanism 
other than mutation of   NOTCH1  . 
    FBW7   is mutated in T-ALL cell lines and primary samples 
  Cellular levels of NICD are determined by the net eff  ects of 
the rates of production and destruction of the protein. The 
SCF-FBW7 ubiquitin ligase plays a critical role in NICD 
degradation that is dependent on an intact PEST domain of 
NOTCH (  25  –  30  ). Other known FBW7 substrates include 
cyclin E, MYC, SR-EBP, and c-Jun (  31  ). FBW7 interacts 
with its substrates via the      propeller formed by its WD40 
repeats after the substrate becomes phosphorylated within 
highly conserved Cdc phosphodegrons (CPDs) (  32, 33  ). Human 
tumors harbor nonsense mutations that truncate FBW7 as 
well as missense mutations that target key arginine residues in 
the WD40 repeats. These mutations disable FBW7  –  substrate 
interactions and impair substrate degradation by FBW7 (  34  –  37  ). 
Mutations aff  ecting CPDs in tumor-derived alleles of both 
  MYC   and   JUN   have been described (  38  –  41  ). Thus, muta-
tions removing or altering the substrate CPD can also lead to 
loss of regulation by FBW7. Because the PEST domain trun-
cations found in human T-ALL are predicted to disrupt 
FBW7 binding to NICD, we hypothesized that   FBW7   mu-
tation could represent an alternative mechanism for NOTCH 
deregulation in human cancers. 
  To test this hypothesis, we sequenced the entire coding 
region of   FBW7   to determine whether mutations aff  ecting 
at one or more points could short-circuit this pathway in 
NOTCH-supported tumors, leading to clinically important 
antitumor eff  ects. 
  Blocking the intramembranous cleavage of NOTCH is 
an especially attractive strategy of targeted therapy. When the 
NOTCH receptor is recognized by its membrane-bound 
ligand, a conformational change exposes the receptor to 
sequential rounds of protease cleavage. Binding of the ligand 
results in proteolytic cleavage of the receptor, fi  rst outside the 
cell by TNF-      –  converting enzyme and then by the     -secretase 
membrane protease complex, releasing the NOTCH intra-
cellular domain (NICD), which translocates to the nucleus 
where it regulates the expression of its target genes, including 
  MYC   and   DELTEX1   (  20  –  23  ). Small molecule inhibitors of 
    -secretase activity are now available that eff  ectively inhibit 
NOTCH signaling in vitro. One commercial product, com-
pound E, induces growth arrest in several diff  erent T-ALL 
cell lines by inhibiting the NOTCH pathway (  11  ). Recently, 
we showed that treatment of T-ALL cells with the MRK-003 
    -secretase inhibitor (GSI) results in prolonged cell cycle 
arrest followed by apoptosis (  24  ). 
  Despite the promise of GSI therapy for tumors driven by 
aberrant NOTCH signaling, most human T-ALL cell lines 
are resistant to these agents and grow normally despite GSI 
treatment. Thus, to establish the molecular basis of GSI resis-
tance in tumor cells, we used T-ALL cell lines as a model 
system to test the ability of GSI treatment to reduce cellular 
levels of NICD, as well as its transcriptional targets   MYC   and 
  DELTEX1  . We found that mutations aff  ecting the FBW7 
ubiquitin ligase occur in GSI-resistant cell lines and are asso-
ciated with sustained NOTCH signaling. Moreover, we 
found   FBW7   mutations in primary T-ALL samples, and the 
mutational spectrum suggests that they produce dominant-
negative   FBW7   alleles. Our fi  ndings implicate   FBW7   muta-
tions in both the pathogenesis of T-ALL and leukemic cell 
resistance to GSIs. 
    RESULTS   
  MRK-003 treatment leads to Notch-dependent 
antiproliferative effects in a subset of T-ALL cell lines 
  To inhibit NOTCH-mediated signal transduction, we treated 
each of 20 T-ALL cell lines with the Merck GSI MRK-003 
(24) at 1     M or with DMSO (vehicle control) for 7 d. To 
study the eff   ects of GSI treatment, we analyzed the cell 
counts, cell cycle profi  les, and apoptosis at various time points 
after treatment. We did not observe any eff  ects on prolifera-
tion or viability at 6 h, 24 h, or 3 d in any of the 20 lines. Five 
of the T-ALL cell lines (DND41, Koptk1, ALL-SIL, HPB-
ALL, and TALL1) were sensitive to GSI treatment, exhibit-
ing two- to threefold fewer live cells in the GSI-treated fl  asks 
compared with DMSO-treated fl  asks on day 7 of treatment 
(  Table I  ).   Cell cycle analysis at that time revealed a G  0  /G  1   cell 
cycle arrest with decreased cells in the S phase in each of the 
fi  ve lines (representative histograms are shown for one line in 
  Fig. 1 A  ).   Annexin V staining showed a two- to fourfold in-
crease in the percentage of cells undergoing apoptosis in the JEM VOL. 204, August 6, 2007 
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lines with increased levels of NICD but without C-terminal 
truncating mutations in   NOTCH1   (RPMI8402, CEM, 
BE13, DU528, HSB2, Jurkat, and PEER) harbored either a 
mutation in   FBW7   or homozygous deletion of the gene, thus 
providing an explanation for persistent NICD expression in 
these lines (  Fig. 1 E  ). Conversely, none of the cell lines with 
  FBW7   mutations had PEST domain mutations in   NOTCH1  , 
suggesting that there is no selective pressure for   FBW7   muta-
tion in cells with stabilized NOTCH1. 
  We also sequenced exons encoding the substrate-binding 
domain (exons 7, 8, 9, 10, and 11) of   FBW7   in 150 primary 
this ubiquitin ligase gene might account for the accumulation 
of NICD in T-ALL cell lines that lacked truncations of the 
NOTCH1 PEST degradation domain. Sequencing of the 
entire coding region of   FBW7   in 20 T-ALL cell lines re-
vealed mutations in 6 of the 20 lines (30%) (  Table I  ). The 
GSI-resistant cell line RPMI8402 harbored a homozygous 
arginine-to-histidine mutation at residue 465; all of the other 
mutations were heterozygous missense mutations of critical 
WD40 arginine residues (465 and 505). One additional cell 
line (BE13) has a homozygous deletion of   FBW7   as deter-
mined by quantitative DNA PCR. Each of the seven cell 
  Table I.    FBW7   mutations in human T-ALL cell lines 
  NOTCH1   status    a   
HD domain PEST domain NICD detected    b     FBW7   status
Sensitive Cell Lines
DND41 heterozygous mutation 
1594 L  →  P
heterozygous insertion 2444 CCSHWAPAAWRCTLFCPRRAPPCP
RRCHPRWSHP*STOP
Yes WT
HPB-ALL heterozygous mutation 
1575 L  →  P
heterozygous insertion 2442 
  EGRGRCSHWAPAAWRCTLFCPRRAPPCPRRCHPRWSHP*STOP
Yes WT
Koptk1 heterozygous mutation 
1601 L  →  P
heterozygous deletion 2515 RVP*STOP Yes WT
ALL-SIL heterozygous mutation 
1594 L  →  P
heterozygous insertion 2476 AHP*STOP Yes WT
TALL1 WT WT No WT
Resistant Cell Lines
RPMI8402 heterozygous insertion 
1584 PVELMPPE
WT Yes homozygous 
mutation 465 R  →  H
CEM heterozygous insertion 
1595 PRLPHNSSFHFL
WT Yes heterozygous 
mutation 465 R  →  H
BE13 homozygous mutation 
1601 L  →  P
WT Yes homozygous 
deletion
DU528 WT WT Yes heterozygous 
mutation 465 R  →  H
HSB2 WT WT Yes heterozygous 
mutation 505 R  →  C
Jurkat WT WT Yes heterozygous 
mutation 505 R  →  C
PF382 heterozygous mutation 
1575 L  →  P
heterozygous insertion 2494 ASCILWTTPPATSYRCLSTPSSPRP
LSPLTSGPSRPRIPTSPTGPRASPALPPACSPRSPAFRRPSSKRRAPRDP
GFLSQAFGRLCALCGCQGRPEEPF*STOP
Yes WT
Molt13 heterozygous mutation 
1601 L  →  P
heterozygous deletion 2515 *STOP Yes WT
Supt7 heterozygous insertion 
1593 F  →  LGA
heterozygous insertion 2429 
AHKTYRCSSRTCSQQTSSSSKACSRHHHHHSR
TLA*STOP
Yes WT
Molt4 heterozygous mutation 
1601 L  →  P
heterozygous deletion 2515 RVP*stop Yes WT
PEER WT WT Yes heterozygous 
mutation 505 R  →  C
Loucy WT WT No WT
Supt11 WT WT No WT
Supt13 WT WT No WT
Molt16 WT WT No WT
  a    Numbers correspond to amino acid residues in NOTCH1.
  b    As determined by western blot analysis.1816   FBW7   MUTATION IN T-ALL | O  ’  Neil et al.
  residues critical for substrate binding (  Table II  ).   As in the 
T-ALL cell lines, none of the primary samples with an 
  FBW7   mutation had C-terminal truncating mutations in 
  NOTCH1  . These results indicate that mutation of   FBW7   
in primary T-ALL may represent an alternative mechanism 
of NOTCH deregulation that contributes to the pathogen-
esis this disease. 
acute myeloid leukemia (AML) samples, 60 primary myelo-
dysplastic syndrome (MDS) samples, and 81 primary T-
ALL samples. Although the AML or MDS samples lacked 
mutations in   FBW7  , 7 of 81 (8.6%) of the T-ALL samples 
harbored mutations in the substrate-binding domain of 
FBW7. All of the mutations in the patient samples were 
heterozygous missense mutations that altered arginine 
  Figure 1.     Treatment with MRK-003 results in cell cycle arrest, apoptosis, and inhibition of NICD production in human T-ALL cell lines. 
(A) Cell cycle analysis of the GSI-sensitive HPB-ALL cell line. Cells were treated with DMSO (vehicle) or 1     M MRK-003 for 7 d, stained with propidium iodide, 
and analyzed by fl  ow cytometry. (B) Annexin V  –  FITC/propidium iodide staining of the DND41 cell line after 7 d in DMSO or 1    M  MRK-003.  Numbers 
represent the percentage of cells in each quadrant. Similar results were observed in other GSI-sensitive cell lines. (C) Cell cycle analysis of the GSI-resistant 
Molt13 cell line after 7 d in DMSO (vehicle) or MRK-003. Similar results were observed for all other GSI-resistant cell lines listed in Table I. (D) Annexin 
V  –  APC/propidium iodide staining of the Molt4 cell line after 7 d in DMSO or 1     M MRK-003. Similar results were observed in all other GSI-resistant cell 
lines. (E) Activated NOTCH1 Western blot analysis. T-ALL cell lines were treated with 1     M MRK-003 for 3 d. Whole cell lysates were subjected to SDS-
PAGE electrophoresis and immunoblotting with the NOTCH1 (V1744) antibody.     JEM VOL. 204, August 6, 2007 
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mutation of another possible NOTCH1 CPD consensus mo-
tif anchored around threonine 2133 (38) did not aff  ect FBW7 
binding (unpublished data). 
  Because two putative CDK8 sites in the T2512 region 
have been previously implicated in NOTCH degradation by 
FBW7 (S2514 and S2517), we also tested the role of these 
residues in FBW7 binding (  26  ). We found that FBW7 bind-
ing was disrupted by the S2514A mutation and that binding 
was restored when S2514 was replaced by a phosphomimetic 
residue (S2514E) (  Fig. 2 D  ). Although these data are consistent 
with a role for S2514 phosphorylation in FBW7 binding, a 
negative charge in the +2 position (relative to the central 
threonine) is not a characteristic CPD feature. We thus mu-
tated S2514 to proline, which conforms to the CPD consen-
sus, and found that S2514P also restored FBW7 binding. 
Thus, although a negative charge is tolerated in the +2 posi-
tion, it is not required for FBW7 binding. We also examined 
the binding of the NICD to each of the three FBW7 isoforms, 
which reside in distinct subcellular compartments (  44  ). The 
  results show that NICD binds to both FBW7     (nucleoplasmic) 
and FBW7     (nucleolar), but not to FBW7     (cytoplasmic), 
supporting the idea that the NICD interacts with FBW7 in 
the nucleus (  Fig. 2 E  ). 
  We next examined the role of T2512 in directing FBW7-
mediated endogenous NICD ubiquitination and, in accord 
with our binding studies, found that the T2512A mutation 
markedly reduces NICD ubiquitination (  Fig. 2 F  ). The ex-
tent to which this mutation inhibited ubiquitination was 
similar to that seen with a C-terminal PEST deletion, termed 
deltaCT, which is defective in ubiquitination by FBW7 (  27  ). 
The small amount of residual ubiquitination could refl  ect ei-
ther basal, T2512A-independent interactions of the NICD 
with FBW7, or could be due to alternative NICD ubiqui-
tination pathways. Finally, we used metabolic labeling and 
pulse chase to compare the half-life of WT-NICD to the 
T2512A mutant in 293 cells. As predicted, the T2512A mu-
tant shows a prolonged half-life, refl  ecting impaired degrada-
tion in vivo (  Fig. 2 G  ). Collectively, these data indicate that 
the T2512 region comprises a functional CPD that directs 
binding interactions between NOTCH and FBW7. 
  The NOTCH1 T2512 region comprises 
an FBW7 phosphodegron 
  As outlined above, loss of FBW7-mediated regulation of its 
substrates can result from mutation of   FBW7   itself or from mu-
tation of the substrate. The PEST domain of NICD is known 
to regulate protein stability and is a hot spot for mutations 
in primary human and mouse T-ALLs (  7, 11  ). Furthermore, 
FBW7 binding to NOTCH is dependent on an intact PEST 
domain (  27  ), strongly suggesting that the NOTCH CPD lies 
within this region. Alignment of the human NOTCH1 PEST 
domain with other FBW7 substrates demonstrated a CPD con-
sensus motif anchored around threonine 2512 (T2512) in hu-
man NOTCH1. This residue is highly conserved across species 
as well as across members of the NOTCH family (  Fig. 2 A  ).   
Notably, T-ALL  –  associated   NOTCH1   PEST mutations iden-
tifi  ed in both human and mouse tumors occur upstream, or 
very nearby, this putative CPD, suggesting that these mutations 
may disrupt its function (  7, 11  ). 
  To determine if the T2512 region contains a functional 
NOTCH CPD, we examined its role in binding interactions 
between the NICD and FBW7. For these studies, we used an 
expression plasmid encoding the mouse NICD, where T2487 
corresponds to human T2512 (human numbering is used to 
refer to this CPD throughout this article). We fi  rst mutated 
T2512 to alanine (T2512A) and cotransfected 293 cells (  Fig. 
2 B  ) or K562 erythroleukemia cells (  Fig. 2 C  ) with FBW7 
and NICD. Because the interaction of FBW7 with its sub-
strates leads to ubiquitination and degradation by the protea-
some, we uncoupled substrate binding from turnover so that 
we could observe stable FBW7  –  substrate interactions. To 
disrupt this pathway, we expressed two previously described 
SCF mutants: (a) dominant-negative cullin-1 (dnCul1), which 
interacts with F-box proteins, but not ubiquitin-conjugating 
enzymes (  42  ), and (b) a truncated version of FBW7 (termed 
Fb-WD), which encodes the WD40 substrate binding do-
mains but lacks the N-terminal domains, including the F-box 
motif, and thus is unable to associate with cullin-1 and with 
the SCF (  43  ). In both cases we found that the T2512A NICD 
mutant showed markedly decreased binding to FBW7 when 
compared with WT-NICD (  Fig. 2, B and C  ). In contrast, 
  Table II.    FBW7   mutations in primary T-ALL patient samples 
Sample    a     NOTCH1   status    b     FBW7   status
HD domain PEST domain
2773 heterozygous mutation 1605 V  →  E WT heterozygous mutation 479 R  →  Q
2788 heterozygous mutation 1601 L  →  P WT heterozygous mutation 465 R  →  H
1179 WT WT heterozygous mutation 465 R  →  C
2748 heterozygous mutation 1586 L  →  P WT heterozygous mutation 479 R  →  Q
368 heterozygous mutation 1748 F  →  S WT heterozygous mutation 465 R  →  H
037 heterozygous mutation 1601 L  →  P WT heterozygous mutation 465 R  →  C
452 heterozygous mutation 1748 F  →  S WT heterozygous mutation 465 R  →  H
  a    The substrate binding encoding exons of   FBW7   were sequenced in 81 primary T-ALL patient samples. Mutations were found in 7 out of 81 (8.6%) Samples with mutations are 
shown.
  b    Numbers correspond to amino acid residues in NOTCH1.1818   FBW7   MUTATION IN T-ALL | O  ’  Neil et al.
To determine if MYC protein levels are aff  ected by treat-
ment with MRK-003 in our panel of T-ALL cell lines, 
we performed Western blot analysis of lysates from a panel 
of 19 T-ALL cells that were either treated with vehicle 
  GSI treatment results in decreased MYC expression in a 
subset of T-ALL cell lines 
  Recent studies have demonstrated that   MYC   is a direct tar-
get of NOTCH in both human and mouse T-ALL (  20  –  22  ). 
  Figure 2.     NOTCH T2512A mutant shows increased stability and decreased binding to FBW7. (A) Alignment of the four human NOTCH proteins, 
as well as Notch proteins from various species, shows strong conservation of the putative NOTCH CPD. Known CPDs are aligned with NOTCH for compari-
son. (B) The T2512A NOTCH mutant is defi  cient in binding to WT FBW7, and the tumor-derived FBW7 arginine mutant (R465C) can no longer bind WT 
NOTCH. Cells were transfected as indicated, and FLAG-FBW7 was immunoprecipitated. Samples were subjected to SDS-PAGE electrophoresis and immuno-
blotting with anti-MYC tag (9E10) to detect transfected Notch proteins. Whole cell lysates were analyzed as indicated to verify expression of transfected 
constructs. (C) Co-immunoprecipitation assays in the K562 erythroleukemia cell line show that T2512A is defi  cient in binding to FBW7 in hematopoietic 
cells. Whole cell lysates were analyzed as indicated to verify expression of transfected constructs. (D) Phosphorylation of S2514 is not required for the 
FBW7  –  Notch ICD interaction. 293a cells were transfected as indicated and analyzed as in B above. (E) NICD preferentially associates with nuclear and 
nucleolar FBW7 isoforms. 293a cells were transfected with the indicated plasmids and analyzed as in B above. (F) In vivo ubiquitination assays show that 
the NOTCH T2512A mutant is resistant to FBW7-mediated ubiquitination. 293a cells were transfected as indicated. Cell lysates were prepared and immuno-
precipitated with anti-HA antibody to pull down ubiquitinated proteins. Samples were subjected to SDS-PAGE electrophoresis and immunoblotted with 
9E10 to detect MYC-tagged NOTCH proteins. Whole cell lysates were analyzed as indicated to verify expression of transfected constructs. (G) The NOTCH 
T2512A mutant has an extended half-life in 293a cells compared with WT NOTCH. 293a cells were transfected with either WT NICD or the T2512A mutant. 
48 h later, cells were pulse labeled in vivo with   35  S-methionine/cysteine and chased in medium with excess unlabeled methionine and cysteine for the 
indicated times. Transfected NOTCH proteins were immunoprecipitated with MN-1 antisera, and samples were subjected to SDS-PAGE electrophoresis. 
Gels were then exposed to x-ray fi   lm.   JEM VOL. 204, August 6, 2007 
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  We also examined if   MYC   mRNA levels responded to 
GSI treatment by performing expression arrays on 18 of the 
T-ALL cell lines treated with DMSO or MRK-003 (1     M) 
for 3 d. We observed either a very modest eff  ect or no eff  ect 
of GSI treatment on the levels of   MYC   RNA in four of the 
resistant lines that express NICD and have mutated   FBW7   
(CEM, BE13, DU528, and HSB2) (  Fig. 5  ).   Hence, the lack 
of down-regulation of   MYC   by GSI treatment in these lines 
is due to mechanisms acting upstream of   MYC   transcription 
rather than at the protein level. In the microarray expression 
analysis, other NOTCH target genes such as   DELTEX1   and 
  SHQ1   (22) (  Fig. 5   and not depicted) were also not aff  ected 
by GSI treatment in the CEM, DU528, BE13, and HSB2 
cell lines. In the PEER cell line, which also has a mutation in 
  FBW7  , we detected residual expression of NICD after 3 d of 
treatment with MRK-003, and quantitative RT-PCR showed 
that   MYC   and   DELTEX1   RNA expression levels did not 
decrease in this line upon GSI treatment (  Fig. 1 E   and not 
depicted). This suggests that the   FBW7   mutations (or homo-
zygous deletion) found in these fi  ve lines result in residual 
signaling through NICD, even in the face of GSI treatment, 
thus sustaining   MYC   transcription and promoting continued 
cell proliferation. 
  Tumor-derived   FBW7   mutants are functionally impaired 
and may act as dominant-negative mutants to prevent 
MYC degradation 
  Because FBW7 is haploinsuffi   cient for tumor suppression (  46  ), 
the single allele   FBW7   mutations most commonly found in 
T-ALL could lead to stabilization of its substrates simply by 
reducing FBW7 activity by 50%. However, if the selective pres-
sure for these mutations consisted simply of loss-of-function 
of one allele, we would predict that we would fi  nd nonsense 
mutations in the   FBW7   gene (  36, 47  ). Our fi  nding of muta-
tional hot spots aff  ecting the three key arginine residues of 
FBW7 argues against this possibility. Instead, we propose that 
(DMSO) or 1     M MRK-003 for 3 d (  Fig. 3  ).   A reduction 
of MYC protein levels upon GSI treatment was apparent in 
8 of the 19 lines (Koptk1, HPB-ALL, DND41, RPMI8402, 
Molt13, PF382, Supt7, and TALL1), including all of the 
GSI-sensitive lines tested (Koptk1, HPB-ALL, DND41, 
and TALL1). 4 of the other 10 lines (Loucy, Supt11, 
Supt13, and Molt16) lack activated NOTCH signaling 
(i.e., NICD was not detectable by Western blot analysis;   Fig. 
1 E   and   Table I  ), and thus we would not expect GSI treat-
ment to aff  ect the expression of NOTCH target genes in 
these lines. The remaining seven cell lines (Jurkat, Molt4, 
PEER, CEM, DU528, BE13, and HSB2) have activated 
NOTCH signaling but do not display decreased MYC ex-
pression upon GSI treatment. Of note, all of the cell lines 
in which MYC expression is not decreased upon GSI treat-
ment are resistant to the drug, reinforcing the importance 
of this NOTCH target gene for T-ALL cell growth. Because 
over  expression  of MYC has been shown to rescue the 
growth-suppressive eff  ects of GSIs (  20, 21  ), lack of MYC 
down-regulation in these T-ALL cell lines may contribute 
to their GSI resistance. 
  Because MYC is also a FBW7 target, we examined MYC 
half-life in a subset of fi  ve T-ALL cell lines (Molt4, DND41, 
KOPTK1, CEM, and Jurkat) by pulse-chase analysis. Although 
MYC half-life was prolonged in each cell line compared with 
a B cell lymphoblastoid cell line (JY) (  Fig. 4  ), it was not in-
creased in cell lines harboring mutations in   FBW7   (CEM and 
Jurkat) compared with those with WT   FBW7  .   This result was 
not surprising because several lymphoblastic leukemia cell lines 
and patient samples have been shown to have aberrantly stabi-
lized MYC (  45  ). Thus, MYC may be stabilized in T-ALL cell 
lines without   FBW7   mutations due to mutations in other 
components of the MYC degradation pathway. Furthermore, 
in some contexts, FBW7 loss may lead to MYC stabilization in 
subcellular compartments (e.g., the nucleolus) without grossly 
altering bulk MYC turnover (  44  ). 
  Figure 3.     GSI treatment results in decreased MYC protein levels in a subset of T-ALL cell lines. T-ALL cell lines were treated with 1    M 
MRK-003 or DMSO for 3 d, and whole cell lysates were prepared using RIPA lysis buffer. Western blot analysis was performed using antibodies against 
MYC and     -actin as a loading control.     1820   FBW7   MUTATION IN T-ALL | O  ’  Neil et al.
  Figure 5.     NOTCH target genes are not decreased upon GSI treatment in T-ALL cell lines with mutant     FBW7    .   MYC   and   DELTEX   RNA levels in 18 
T-ALL cell lines after 3 d of 1     M MRK-003 GSI treatment (compared with DMSO-treated cells) as determined by microarray gene expression analysis. 
Values are a log  10   ratio of the expression level of   MYC   and   DELTEX   in MRK-003  –  treated cells compared with DMSO-treated cells.     
  Figure 4.     T-ALL cell lines have increased MYC half-life. (A) T-ALL cell lines with WT   FBW7   (Molt4, DND41 and KOPTK1) were pulse-labeled in 
vivo with   35  S-methionine/cysteine and chased in medium with excess unlabeled methionine and cysteine for the indicated times. Endogenous MYC was 
immunoprecipitated from an equal number of cells for each time point and analyzed by gel electrophoresis.   35  S-labeled MYC from each sample was 
quantitated by phosphoimager. The rate of degradation of MYC for each cell line is represented in the graph by best-fi  t exponential lines. Half-lives of 
MYC were calculated from exponential line equations. (B) Pulse-chase experiments were similarly performed on T-ALL cell lines with mutant   FBW7   (CEM 
and Jurkat). All T-ALL cell lines analyzed have increased MYC half-life compared with JY cells, a B cell lymphoblastoid cell line.   JEM VOL. 204, August 6, 2007 
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were unable to promote MYC degradation (  Fig. 6 B  ). We 
also examined whether a T-ALL  –  derived FBW7 mutant can 
dominantly interfere with FBW7-driven MYC degradation 
by expressing either increasing amounts of FBW7-     or a 
mixture of a fi  xed amount of FBW7-     in combination with 
increasing amounts of FBW7-    -R465C. This analysis sug-
gests that the mutant impairs FBW7-driven MYC degrada-
tion in a dose-dependent manner (  Fig. 6 C  ). 
  At least two mechanisms may contribute to the dominant-
negative activities of the mutant FBW7 proteins. The fi  rst 
is suggested by our fi  nding that the FBW7 mutants still in-
teract with Myc through a binding interaction independent 
of the MYC CPD that cannot promote MYC degradation. 
Hence, in the case of MYC, they may simply compete with 
WT FBW7 for MYC binding. However, a second mecha-
nism of dominant-negative function is suggested by recent 
fi  ndings that FBW7 (and its orthologs) form dimers (  48  –  51  ), 
thus raising the possibility that WT and mutant FBW7 pro-
teins form heterodimeric dominant-negative complexes that 
are unable to degrade MYC. However, because mutation of 
the FBW7 dimerization region also disrupts its noncanonical 
binding interaction with MYC, we cannot currently distin-
guish between these two possibilities (unpublished data). We 
thus propose that   FBW7   mutations may contribute to T-ALL 
pathogenesis and GSI resistance by leading to the stabilization 
of MYC as well as NICD. 
    DISCUSSION   
  The early successes of molecularly targeted therapy, such as 
imatinib mesylate directed against the BCR-ABL fusion pro-
tein in chronic myelogenous leukemia, stimulated enormous 
interest in subverting abnormal signaling pathways in cancer 
cells. The NOTCH signaling cascade infl  uences normal devel-
opment by regulating diff  erentiation, proliferation, and apop-
tosis (  52  ). Activation of the NOTCH signaling pathway is 
fi  rmly established in T-ALL and is likely involved in the gene-
sis of many other tumor types (  53  ). Thus, it is not surprising 
that eff  orts to block NOTCH signaling as a novel therapeutic 
strategy are under way in T-ALL as well as in solid tumors. 
One of the most promising approaches has been to inhibit 
NOTCH receptor signaling using GSIs. This strategy sup-
presses the generation of NICD and thus, in principle, should 
inhibit the downstream transcriptional events normally in-
duced by this key signaling component after it traverses to the 
nucleus. Although eff  ective against some T-ALL cell lines, 
GSIs do not uniformly eliminate leukemic cells with activated 
NOTCH signaling. Understanding the mechanisms of GSI 
resistance may lead to better treatments for T-ALL. 
  We found missense   FBW7   mutations or homozygous 
  FBW7   deletion in GSI-resistant T-ALL cell lines and in pri-
mary T-ALL samples. Moreover, we have defi  ned the NOTCH 
phosphodegron and demonstrated that the mutant forms of 
FBW7 found in T-ALL cannot bind to the NICD. Each T-
ALL cell line with constitutive NICD expression harbored 
either   NOTCH1   PEST domain or   FBW7   mutations, suggesting 
that these two classes of mutations provide a mutually exclusive 
the restricted mutational spectrum indicates a strong selection 
for expression of an FBW7 protein that is defective for pro-
ductive substrate interactions and/or turnover, which sug-
gests activity as a dominant-negative allele. 
  To explore this possibility, we analyzed each of the three 
mutant FBW7 proteins identifi  ed in T-ALL (  Tables I and II  ) 
for their ability to bind to both MYC and NOTCH. As ex-
pected, the mutants were defective in NOTCH binding, al-
though FBW7R479Q showed a modest amount of residual 
binding (  Fig. 6 A  , right).   In contrast, each of the mutant 
FBW7 proteins bound to MYC, consistent with our recent 
fi  nding that in addition to its canonical interaction with the 
MYC threonine 58 (T58) CPD, full-length FBW7 also binds 
to MYC through a second interaction that is independent of 
the T58 CPD (  Fig. 6 A  , left, and unpublished data). Impor-
tantly, although these FBW7 mutants bound to MYC, they 
  Figure 6.     Mutant     FBW7     cannot bind to NICD and acts in a 
dominant-negative manner to prevent MYC degradation. (A) FBW7 
arginine point mutants effi  ciently co-precipitate with MYC but not with 
NOTCH. 293a cells were transfected with the indicated plasmids. Whole 
cell lysates were subjected to immunoprecipitation with anti-FLAG, and 
resulting samples were analyzed via immunoblotting for either MT-
NOTCH or HA-MYC as indicated. Whole cell lysates were also analyzed 
directly by SDS-PAGE and immunoblotting for FLAG-FBW7, HA-MYC, or 
MT-NOTCH as indicated to verify expression of transfected constructs. 
dnCul1 was included in all transfections to block FBW7-mediated pro-
teasomal degradation. (B) T-ALL  –  associated FBW7 mutants are unable 
to mediate MYC degradation. 293a cells were transfected as indicated. 
Whole cell lysates were subjected to SDS-PAGE and immunoblotting for 
either HA-MYC or FLAG-FBW7 as indicated. (C) Tumor-derived FBW7 
mutants dominantly inhibit MYC turnover by WT-FBW7. 293a cells 
were transfected with a constant amount of HA-MYC with increasing 
amounts of either FLAG-FBW7-     or a combination of a constant amount 
(500 ng) of FLAG-FBW7-     and increasing amounts of FLAG-FBW7-   -
R465H  (1 – 5     g). The ratios of mutant to WT FBW7 expression are indi-
cated above lanes 7  –  9. HA-cdk2, which does not affect turnover of MYC 
by FBW7, is included as a transfection control. Whole cell lysates were 
subjected to SDS-PAGE and immunoblotting for HA-MYC, HA-cdk2, or 
FLAG-FBW7 as indicated.     1822   FBW7   MUTATION IN T-ALL | O  ’  Neil et al.
sent and Institutional Review Board approval was obtained to use leftover 
patient material for research purposes. 
  Cell lines.     T-ALL cell lines were obtained from American Type Culture 
Collection or Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH. 293a cells were provided by S. Reed (The Scripps Research Insti-
tute, La Jolla, CA). 
  Treatment of T-ALL cell lines with MRK-003.     T-ALL cell lines were 
plated at a density of 5      10  4    –  1.5      10  5   cells per ml (depending on dou-
bling time) and were treated with either DMSO or 1     M MRK-003 for 
0 h, 6 h, 24 h, 3 d, or 7 d. For each time point, triplicate fl  asks were 
analyzed by the trypan blue exclusion assay to determine cell viability. 
For propidium iodide staining to analyze the cell cycle profi  le, cells were 
washed with PBS, stained in a PBS buff  er containing 50     g/ml propidium 
iodide and 200     g/ml RNase A, and analyzed on a Becton Dickinson 
FACSCalibur Instrument. For annexin V staining to determine the per-
centage of cells undergoing apoptosis, the annexin V  –  FITC (or annexin 
V  –  APC) Apoptosis detection kit I (BD Biosciences) was used according to 
the manufacturer  ’  s instructions. 
  Microarray gene expression analysis.     Total RNA isolated from cultured 
cells was used to make fl  uorescently labeled cRNA that was hybridized to 
DNA oligonucleotide microarrays as described previously (  55, 56  ). Human 
microarrays contained oligonucleotide probes corresponding to     21,000 
genes. All oligonucleotide probes on the microarrays were synthesized in situ 
with inkjet technology (Agilent Technologies) (  55  ). After hybridization, 
  arrays were scanned and fl  uorescence intensities for each probe were recorded. 
Ratios of transcript abundance (experimental to control) were obtained after 
normalization and correction of the array intensity data. Gene expression 
data were analyzed with the Rosetta Resolver gene expression analysis soft-
ware (version 6.0; Rosetta Biosoftware). Microarray data have been depos-
ited in the GEO database under accession number GSE8416. 
  Western blotting.     For analysis of endogenous protein expression, T-ALL 
cell lines were treated with MRK-003 for 3 d and lysed in RIPA buff  er. 
Blots were probed with 9E10 anti-MYC antibody (1:500; Santa Cruz Bio-
technology, Inc.), the cleaved NOTCH1 (Val1744) antibody (1:1,000; Cell 
Signaling Technology) as described previously (  24  ), and anti  –      -actin 
(1:7,000; Abcam) for the loading control. Signal was detected with Super-
Signal West Femto ECL reagent (Pierce Chemical Co.). For transfections, 
MYC-tagged proteins were detected with 9E10 hybridoma supernatant 
(1:4), HA-tagged proteins were detected with HA-11 (1:1,000), and FLAG-
tagged proteins were detected with M2 anti-FLAG (1:4,000; Sigma-Aldrich). 
These same antibodies were conjugated to protein G sepharose and used for 
immunoprecipitations as described previously (  57  ). 
  Mutation detection.     The entire coding region of   FBW7   was sequenced in 
genomic DNA isolated from the 20 T-ALL cell lines. Exons 7, 8, 9, 10, and 
11 of   FBW7   were sequenced in primary patient samples. All sequencing was 
performed at Agencourt Bioscience Corporation. Residues are numbered 
according to their location in the      isoform of FBW7 (GenBank RefSeq 
NM_033632). 
  Plasmids and transient transfections.     The following expression plasmids 
have been described (43, 44): pFLAG-FBW7-    , -    , and -    ; pFLAG-FbWD; 
pFLAG-FBW7-    -R465H (also termed R298H); and HA-MYC, HA-dncul1, 
and HA-ubiquitin. All mutagenesis were performed by the QuickChange 
method (Stratagene) and confi  rmed by sequencing. Point mutations in the 
FBW7 common region R465H, R479Q, and R505C were generated by 
site-directed mutagenesis using pFLAG-FBW7 vectors as template. Although 
numbering is diff  erent between isoforms, the      numbering is used for simplic-
ity. CS2-mNICD-MT was provided by R. Kopan (Washington University, 
St. Louis, MO). It encodes the mouse Notch1 intracellular domain from 
Val1744 to the end of the WT protein and includes six in-frame MYC epitope 
means of prolonging the NICD half-life. We also show that 
the expression of NOTCH target genes including   DELTEX1   
and   MYC   are not aff  ected by GSI treatment in fi  ve resistant 
T-ALL cell lines with mutations in  FBW7   (CEM, BE13, PEER, 
DU528, and HSB2), demonstrating that the mechanism 
of resistance in these leukemias lies upstream of   MYC   and 
  DELTEX1   transcription. It appears that in these T-ALL lines, 
one consequence of   FBW7   mutation is stabilization of the 
NICD resulting in sustained NOTCH signaling, and thus pro-
moting resistance to GSIs. However, other FBW7 substrates, 
such as MYC, may also account for selection for   FBW7   muta-
tions and for GSI resistance in T-ALL, as suggested by our 
fi  nding that ALL-associated   FBW7   mutations can dominantly 
inhibit MYC degradation. 
  An important question is why   FBW7   mutation confers 
GSI resistance, whereas NOTCH PEST domain truncations 
that remove the FBW7 interaction domain do not. In each 
cell line with PEST mutations, only one allele is aff  ected by 
these heterozygous mutations, leaving the remaining normal 
allele, which encodes an NICD that is stabilized in the pres-
ence of mutant FBW7. Thus, although the amount of in-
creased NOTCH activity resulting from the single allele 
PEST mutations may be suffi   cient to underlie the primary 
selection for these mutations, disruption of FBW7 function 
may be more active in sustaining NOTCH signaling and also 
may prolong the half-life of MYC (as well as other substrates), 
thus promoting GSI drug resistance. 
  The association between   FBW7   mutations and resistance 
to GSIs has implications for clinical testing of these agents in 
patients whose cancers show deregulation of the NOTCH 
pathway. Molecular analysis of the   FBW7   gene, as well as 
genes encoding the relevant NOTCH receptors and other 
key components of the NOTCH signaling pathway, such as 
NUMB, may contribute to identifi  cation of patients likely to 
be most responsive to GSI therapy. Because Myc has recently 
been shown to be an important target of Notch in mammary 
tumorigenesis as well as in T-ALL (  5  ), it might also be possi-
ble to overcome GSI resistance by combining GSIs with other 
drugs that block the MYC pathway to synergistically reduce 
MYC levels and block tumor cell growth. One attractive 
candidate is TMPyP4, a cationic porphyrin that binds to and 
stabilizes guanine quadruplexes in DNA.   MYC   contains a se-
quence in its promoter that forms a guanine quadruplex, and 
TMPyP4 has been shown to inhibit   MYC   transcription and 
the growth of tumor cells in vivo (  54  ). Thus, TMPyP4 or 
other agents that inhibit   MYC   transcription may be useful in 
combination with GSIs to overcome resistance in patients 
harboring   FBW7   mutations. Pharmacologic or genetic strat-
egies that restore the normal function of FBW7 in tumor cells 
could also be therapeutically useful. 
  MATERIALS AND METHODS 
  Patient samples.     Bone marrow or peripheral blood samples were collected 
at diagnosis from T-ALL patients at the Sophia Children  ’  s Hospital/Erasmus 
MC and the Dutch Childhood Oncology Group, as well as from AML, 
MDS, and T-ALL patients at Dana-Farber Cancer Institute. Informed con-JEM VOL. 204, August 6, 2007 
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tags at the C terminus. Mutagenesis of this construct was used to generate the 
T2512A, S2514A, S2514E, and S2514P mutants. The deltaCT mutation, 
generated by PCR, deletes the PEST domain but maintains the C-terminal 
MYC tags. 293A cells were transfected by the calcium phosphate precipita-
tion method as described previously (  57  ). Cells were harvested at 36  –  48 h 
after transfection using TENT buff  er (50 MM Tris-Cl, pH 8.0, 2 mM EDTA, 
150 mM NaCl, 1% Triton X-100) (  30  ) with protease and phosphatase inhib-
itors and analyzed by immunoprecipitation and Western blotting as described 
previously (  57  ). 
  Metabolic labeling and pulse chase.     NICD pulse-chase assays were per-
formed as described previously (  43  ). In brief, 293a cells were transfected 
with plasmids encoding MYC-tagged NICD or NICD T2512A. At 36 h af-
ter transfection, cells were preincubated with media lacking cysteine and 
methionine, pulsed with media containing Trans 35S label, and chased with 
media with cold methionine. Samples were obtained at the indicated time 
points and immunoprecipitated with anti-Notch serum MN1, a mouse 
monoclonal antibody recognizing the NICD (provided by I. Bernstein, Fred 
Hutchinson Cancer Research Center, Seattle, WA). MYC pulse-chase ex-
periments were performed as described previously (  45  ). 
  Ubiquitination assays.     Cell-based ubiquitination assays were performed as 
described previously (  58  ). In brief, transiently transfected 293a cells were 
harvested at 48 h after transfection. Cells were trypsinized, rinsed once with 
PBS, and lysed in 100     l 2% SDS in TBS (10 mM Tris-HCl, pH 8.0, 150 
mM NaCl) with boiling for 10 min. These samples were diluted at 1:10 with 
1% triton in TBS containing protease inhibitors, 5 mM N-ethymaleimide, 
and 5 mM MG132, sonicated, precleared with protein G sepharose, and 
centrifuged to pellet-insoluble debris. Aliquots were removed for Western 
blot analysis, and the remaining lysates were immunoprecipitated with anti-
HA antisera prebound to protein G sepharose. Samples were analyzed by 
SDS-PAGE and probed with 9E10 to visualize MYC-tagged ubiquitinated 
Notch proteins. 
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